Gastroenterology

Swift Uptake for Mvasi Suggests Provider Comfort With Use

January 18, 2021

Tony Hagen

Article

Investigators looked at the first 9 months of use following the launch of the bevacizumab biosimilar Mvasi to gauge physician comfort with this agent across tumor types.

With New Policy, CMS Promises to Exit "Stone Age" of Health Information

January 15, 2021

Tony Hagen

Article

CMS looks to speed up health information transfer by putting faxes in the past. It also aims to set deadlines for payers to respond to prior authorization requests.

Infliximab Biosimilar Switching Study Yields Evidence of Safety, Efficacy

January 14, 2021

Deana Ferreri, PhD

Article

A need for clinical evidence on the efficacy and safety of infliximab switching led the authors to pursue this investigation.

Economists Probe Cost-Effectiveness of Biosimilars

January 7, 2021

Tony Hagen

Article

Authors of a review found that biosimilar uptake and market share are not in themselves sufficient to establish whether these agents will lead to savings.

Adalimumab Biosimilars Face Product Obsolescence Before Launch

January 6, 2021

Tony Hagen

Article

Product differentiation by concentration is a threat to the multiple adalimumab biosimilars approved but not yet launched.

Investigators Chart ABP 980 Biosimilar Uptake in European Clinics

January 4, 2021

Tony Hagen

Article

Among patients treated for metastatic breast cancer, 40% switched to ABP 980.

Amgen's Bourdon Discusses Riabni Rollout in the United States

December 23, 2020

Tony Hagen

Article

Christophe Bourdon, senior vice president and general manager of US Oncology for Amgen, discussed the development and marketing plan for the company's newly approved rituximab biosimilar.

Sandoz Canada Gains Marketing Approval for Adalimumab Biosimilar

December 18, 2020

Tony Hagen

Article

The Canada Health approval for Hyrimoz will be followed by a launch in February 2021, Sandoz Canada said.

Opinion: Boehringer Ingelheim May Win Regulatory Language Change Despite Weak Argument

December 12, 2020

Sarfaraz K. Niazi, PhD

Article

Boehringer Ingelheim's argument hinges on how "strength" of formulation is defined in regulatory language.

Alvotech Scientific Officer Describes Company's Global Biosimilars Strategy

November 25, 2020

Tony Hagen

Article

Joseph E. McClellan, PhD, MBA, discussed navigation of regulatory hurdles as the company continues its quest to line up distribution partnership deals across the globe.

x